Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...

NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...

In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal ...

Since then, Biogen decided to opt out of their partnership on essential tremor candidate SAGE-324 after disappointing results ...

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

Sage Therapeutics was in focus after it rejected Biogen's acquisition proposal. Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding ...

Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of ...